Examined marker HER-2 is a critical and therapeutic target, especially in breast, gastric, and lung cancer, mainly assessed via IHC and fluorescence in situ hybridization to determine the degree of tumor aggressiveness. This evidence concerns the gene ERBB2 and neoplasm.